<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370288</url>
  </required_header>
  <id_info>
    <org_study_id>IR.MUMS.REC.1399.122</org_study_id>
    <nct_id>NCT04370288</nct_id>
  </id_info>
  <brief_title>Clinical Application of Methylene Blue for Treatment of Covid-19 Patients</brief_title>
  <acronym>Covid-19</acronym>
  <official_title>The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event.
      Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized
      form, blue color) has been used in many different areas of clinical medicine, ranging from
      malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied
      for the treatment of COVID-19 according to the scientific evidences.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2020</start_date>
  <completion_date type="Anticipated">September 21, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients remaining free of need for mechanical ventilation in both groups</measure>
    <time_frame>Day 7</time_frame>
    <description>All patient will be assess for changes in disease severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Pa02/Fi02 ratio in both groups</measure>
    <time_frame>Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital stay in both group.</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intensive Care Unit stay in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days free of dialysis in both groups</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive proteins</measure>
    <time_frame>3-5 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC Count</measure>
    <time_frame>3-5 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Covid-19 patients treated with standard medical therapy (supportive therapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Covid-19 patients treated with mixture of MCN (Methylene blue, vitamin C, N-acetyl cysteine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCN (Methylene blue, vitamin C, N-acetyl cysteine)</intervention_name>
    <description>A mixture of MCN will be injected to covid-19 patients.</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Leucomethylene Blue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed case of Covid-19 (by RT-PCR, HRCT)

          2. Admission to Intensive Care Unit

          3. Need for intubation and mechanical ventilation (PaO2/FiO2 &lt; 100-200)

          4. Written informed consent

        Exclusion Criteria:

          1. Pregnancy and breastfeeding

          2. History of G6PDH deficiency

          3. Preadmission anticoagulation

          4. Severe renal insufficiency (glomerular filtration rate &lt;30 mL/min/1.73m2)

          5. Medical records of cirrhosis

          6. Active chronic hepatitis

          7. Severe hepatic disease defined by GOT or GPT levels three times above the normal upper
             limit

          8. Patients with history of allergic reaction or significant sensitivity to Methylene
             blue

          9. Treatment with immunosuppressive agents

         10. Use of other investigational drugs in the moment of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daryoush Hamidi Alamdari, Ph.D</last_name>
    <phone>+98 51 3882 8574</phone>
    <email>hamidiad@mums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir Yarahmadi, Ph.D</last_name>
    <phone>+98 51 3882 8574</phone>
    <email>yarahmadiA961@mums.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imam Reza Hospital</name>
      <address>
        <city>Mashhad</city>
        <state>Razavi Khorasan</state>
        <zip>9137913316</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad Bagheri Moghaddam, M.D</last_name>
      <phone>05138412081</phone>
      <email>bagheria@mums.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Daryoush Hamidi Alamdari</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Coronavirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

